K2M Group (KTWO) Given “Buy” Rating at Barclays

K2M Group (NASDAQ:KTWO)‘s stock had its “buy” rating reissued by equities researchers at Barclays in a research note issued to investors on Tuesday, January 9th. They presently have a $25.00 price objective on the medical device company’s stock. Barclays’ price target would indicate a potential upside of 19.90% from the stock’s previous close.

Several other analysts have also recently weighed in on the stock. Needham & Company LLC lifted their price objective on shares of K2M Group from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Tuesday, January 9th. Zacks Investment Research cut shares of K2M Group from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. BidaskClub cut shares of K2M Group from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Wells Fargo & Co cut shares of K2M Group from an “outperform” rating to a “market perform” rating and set a $23.00 target price for the company. in a research report on Monday, December 4th. Finally, Oppenheimer reaffirmed a “buy” rating and set a $24.00 price target on shares of K2M Group in a report on Friday, November 10th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. K2M Group presently has an average rating of “Buy” and an average target price of $24.50.

K2M Group (NASDAQ KTWO) traded up $0.40 during midday trading on Tuesday, hitting $20.85. 268,307 shares of the stock were exchanged, compared to its average volume of 363,984. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 0.29. The firm has a market cap of $921.07, a PE ratio of -21.72 and a beta of 1.34. K2M Group has a one year low of $16.44 and a one year high of $25.99.

K2M Group (NASDAQ:KTWO) last posted its earnings results on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). K2M Group had a negative return on equity of 16.02% and a negative net margin of 16.22%. The company had revenue of $62.65 million for the quarter, compared to analyst estimates of $62.69 million. During the same quarter in the prior year, the business posted ($0.19) EPS. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. equities analysts anticipate that K2M Group will post -0.85 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KTWO. Schwab Charles Investment Management Inc. raised its holdings in K2M Group by 32.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 174,070 shares of the medical device company’s stock worth $4,241,000 after buying an additional 42,290 shares during the last quarter. First Trust Advisors LP bought a new stake in shares of K2M Group in the 2nd quarter worth $1,270,000. Rhumbline Advisers grew its stake in shares of K2M Group by 49.2% in the 2nd quarter. Rhumbline Advisers now owns 43,165 shares of the medical device company’s stock worth $1,051,000 after acquiring an additional 14,241 shares in the last quarter. Legal & General Group Plc grew its stake in shares of K2M Group by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 9,561 shares of the medical device company’s stock worth $232,000 after acquiring an additional 2,798 shares in the last quarter. Finally, BNP Paribas Arbitrage SA grew its stake in shares of K2M Group by 5,175.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock worth $109,000 after acquiring an additional 4,399 shares in the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “K2M Group (KTWO) Given “Buy” Rating at Barclays” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://stocknewstimes.com/2018/01/20/k2m-group-ktwo-earns-buy-rating-from-barclays.html.

About K2M Group

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Analyst Recommendations for K2M Group (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply